Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 6/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.37 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25327778 | 0.91 | RIPK1 (0.34) | RIPK1PDK2PDK1PDK3PDK4 | |
| SCHEMBL25327613 | 0.90 | MDM2 (0.37) | RIPK1PDK2PDK1PDK3PDK4 | |
| SCHEMBL25327269 | 0.90 | RIPK1 (0.33) | RIPK1PDK2PDK1PDK3PDK4 | |
| SCHEMBL25324212 | 0.89 | RIPK1 (0.39) | RIPK1PDK2PDK1PDK3PDK4 | |
| SCHEMBL25327493 | 0.88 | GRIN2B (0.39) | — | |
| SCHEMBL25914681 | 0.87 | NR1H2 (0.43) | RIPK1NR1H3NR1H2 | |
| SCHEMBL25326369 | 0.84 | TACR1 (0.36) | PDK2PDK1PDK3PDK4 | |
| SCHEMBL25325212 | 0.84 | HDAC4 (0.38) | PDK2PDK1NR1H3NR1H2 | |
| SCHEMBL25327457 | 0.84 | NR1H2 (0.41) | RIPK1NR1H3NR1H2 | |
| SCHEMBL25326301 | 0.82 | PSEN1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023146991-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |